Entrada Therapeutics announces annual shareholder meeting

• Entrada Therapeutics scheduled 2026 annual stockholder meeting for June 10, 2026, to be held virtually.
• Vote set for election of 2 Class II directors for terms running to 2029.
• Shareholders to consider ratification of Ernst & Young as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
• Ballot includes Amendment No. 1 to 2021 Stock Option and Incentive Plan to add “Outstanding Shares” definition, incorporating pre-funded warrants into evergreen share reserve calculation.
• Meeting agenda also includes Amendment No. 1 to 2021 Employee Stock Purchase Plan to add “Outstanding Shares” definition, incorporating pre-funded warrants into evergreen share reserve calculation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001689375-26-000021), on April 24, 2026, and is solely responsible for the information contained therein.